Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.

• 影响指数: 6.075
• 发表时间: 04 2018
• 来源期刊: Cephalalgia
• DOI: 10.1177/0333102418758283
• PMID: 29504482
• 文章类型: Journal Article
• 中科院分区: Q1
• 方向: 医学
• 作者列表: Tassorelli C,Diener HC,Dodick DW,Silberstein SD,Lipton RB,Ashina M,Becker WJ,Ferrari MD,Goadsby PJ,Pozo-Rosich P,Wang SJ,

关键词: Chronic migraine; clinical trials; drugs; headache; preventive treatment

Mesh: Adult; Age of Onset; Anxiety / diagnosis; Chronic Pain / drug therapy prevention & control; Clinical Protocols / standards; Controlled Clinical Trials as Topic / standards; Cross-Over Studies; Depression / diagnosis; Double-Blind Method; Endpoint Determination; Female; Health Surveys; Humans; Male; Migraine Disorders / drug therapy prevention & control; Prescription Drug Overuse / statistics & numerical data; Quality of Life; Secondary Prevention / standards; Sex Factors; Young Adult

Abstract

Background Quality clinical trials form an essential part of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for Controlled Trials of Drugs in Migraine. In 2008, the Committee published the first specific guidelines on chronic migraine. Subsequent advances in drug, device, and biologicals development, as well as novel trial designs, have created a need for a revision of the chronic migraine guidelines. Objective The present update is intended to optimize the design of controlled trials of preventive treatment of chronic migraine in adults, and its recommendations do not apply to trials in children or adolescents.